Venture Capital News: Breaking Venture Capital News, Comments and Articles. - Page: 3

Sabra Health Care REIT, Inc. Discusses Capital Markets Strategy; Updates 2013 Guidance

IRVINE, Calif., May 23, 2013 (GLOBE NEWSWIRE) -- Certain subsidiaries of Sabra Health Care REIT, Inc. ("Sabra," the "Company" or "we") (Nasdaq:SBRA) completed the issuance of $200 million aggregate principal amount of 5.375% senior notes due 2023 (the "2023 Notes"). Sabra expects to use a portion of the net proceeds of the offering to redeem $113.8 million of the 8.125% senior notes due 2018 (the...

GSV Capital Corp. to Present at the Raymond James Internet/Software Crossover Conference on May 29, 2013

WOODSIDE, Calif., May 23, 2013 (GLOBE NEWSWIRE) -- GSV Capital Corp., ("GSV"), (Nasdaq:GSVC), today announced that management will present at the Raymond James 2013 Internet/Software Crossover Conference being held May 29-30, 2013 at The Ritz-Carlton in Half Moon Bay, CA. Management will present on Wednesday, May 29 at 3:55 p.m. PT. A live webcast will be accessible from the Investors section o...

Theravance to Present at Investor Conferences in June 2013

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/23/13 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the following investor conferences in June 2013: Jefferies 2013 Global Healthcare Conference Grand Hyatt, New York City, NY Wednesday, June 5, 2013 10:30 a.m. ET Goldman Sachs 34th Annual Global Healthca...

VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt

SEATTLE, WASHINGTON -- (Marketwired) -- 05/23/13 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE: VPT) (OTCQX: VPTDF) announces that it has completed the first of its two previously announced non-brokered private placements. The Company has issued an aggregate of US$748,000 principal amount of non-convertible secured debentures (the "Non-Unit Debentures") which matu...

Wireless Capital Partners, LLC Announces Promotion of Paul Hwang

LOS ANGELES, May 23, 2013 (GLOBE NEWSWIRE) -- Wireless Capital Partners, LLC ("Wireless Capital") announced today that Paul Hwang has been promoted to Chief Operating Officer / Executive Vice President. Mr. Hwang joined Wireless Capital in 2003 and most recently served as Chief Information Officer / Executive Vice President where he was responsible for all process, systems, and business develop...

Green PolkaDot Box Incorporated Retains Merriman Capital as Capital Markets Advisor

AMERICAN FORK, Utah, May 23, 2013 (GLOBE NEWSWIRE) -- Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX:MERR), announced today that it has been retained as capital markets advisor to Green PolkaDot Box Incorporated ("the Company") (OTC PINK: GPDB). In this capacity, Merriman will advise Green PolkaDot Box management on various strategic initiatives f...

Cynapsus Therapeutics Reports First Quarter 2013 Financial Results and Recent Developments

TORONTO, ONTARIO -- (Marketwired) -- 05/23/13 -- Cynapsus Therapeutics Inc. (TSX VENTURE: CTH), developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the three months ended March 31, 2013. Unless specified otherwise, all amounts are in Ca...

Translation regulator-focused [eFFECTOR Therapeutics] raises $45mm through Series A round

Newly formed [eFFECTOR Therapeutics Inc.] has raised $45mm in Series A funding from US Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners, and Mission Bay Capital. US Venture, Abingwor...

Portola, Alcobra price IPOs

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) raised $122.1 million and Alcobra Ltd. (NASDAQ:ADHD) raised $25 million after pricing their IPOs on Wednesday. Portola sold 8.4 million shares at $14.50, the mid-point of its proposed $13-$16 range. The pric...

CORRECTING and REPLACING H&Q Healthcare Investors Declares Stock Distribution

First graph, third sentence of release dated May 17, 2013 should read: The Fund will trade ex-distribution on May 23, 2013. (sted The Fund will trade ex-distribution on May 24, 2013.) The corrected release reads: H&Q HEALTHCARE INVESTORS DECLARES STOCK DISTRIBUTION On May 17, 2013, H&Q Healthcare Investors declared a stoc...

Remote Medical International Uses $8M in Capital to Embark on Expansion

When a worker on a remote island in the South Pacific had a heart attack, a physician and a nurse were there from Remote Medical International to treat his symptoms. Within hours, Remote Medical operations specialists back at the company’s Seattle headquarters secured a plane and a crew to fly the man 2,400 miles to a Honolulu hospital for treatment, whe...

Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in Proof-of-Concept Clinical Trial

Data, published in Frontiers in Neurology, will be presented at the Alzheimer’s Association International Conference (AAIC) in Boston “This simple eye test has the potential to transform the way Alzheimer’s disease is detected and managed.” Carl Sadowsky, MD, FAAN, Medical Director Premiere Research Institute, West Palm Beach, Fla. Cog...

KFx Medical Corporation Announces Allowance from United States Patent Office of Two Additional Orthopedic Surgical Patents

KFx Medical Corporation announced that it received Notice of Allowance of claims in two additional patent applications broadly covering its AppianFx anchors and anchors for use in knotless double row rotator cuff repair. “Our patent counsel, Knobbe, Martens, Olson and Bear LLP has done a superb job for us in the prosecution of our patent estate....

Mythbusters: Biotech Venture Capital

This from the LifeSci VC blog this morning. A post on the myths that persist in the popular conscience about biotech venture capital. Since they are characterized as "myths", then it follows that data shows them not to be true. Without further ado: R...

The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients

WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6 million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with...

Principal Financial Group Announces Strategic Alliance with Accountable Health, Inc.

The Principal to transfer ownership of Principal Wellness to Accountable Health The Principal Financial Group®, a global investment management leader, today announced a strategic agreement with Accountable Health, Inc. to offer comprehensive wellness programs to business and health plan clients through Accountable Health. Under terms of the agr...

Direct Flow Medical Transcatheter Aortic Valve System Demonstrates Excellent 30 Day Outcomes Following Full Enrollment of DISCOVER CE Mark Trial

Results Presented in Oral Presentation at EuroPCR Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced that it has met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE Mark Trial by achieving 99 percent freedom from all-cause mortality at 30 days. Patients were...

Guided Therapeutics Announces Private Placement of Convertible Preferred Stock and Warrants

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has entered into definitive agreements with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross proceeds to Guided Therapeutics are expected to be approximately $2.6 million, prior to...

Debunking Myths About Biotech Venture Capital

There are lots of myths about venture capital and biotech in particular, as noted previously on this blog.  Many of these myths are deeply held beliefs about returns, what works and what doesn’t, and the state of the industry.  Told

First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System

WILMINGTON, Del. and MUNICH, May 22, 2013 /PRNewswire/ -- JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today its first interim results of the JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere AoRtic Stenos...

TheraCoat Has Completed a Capital Raising of $7M led by Pontifax and Chaim Hurvitz's CHealth Fund

TheraCoat Ltd. (TheraCoat), a clinical stage specialty pharmaceutical company focused on innovative drug-delivery solutions for the treatment of intra-cavital diseases, announces today the completion of a successful capital raise of $7M from private investors and venture Funds, both in Israel and abroad. Amongst the investors are Pontifax, and Chaim Hurvit...

Clinical Data on TetraLogic Pharmaceuticals’ Smac Mimetic Birinapant to Be Presented at ASCO

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that data from two clinical studies investigating its lead Smac mimetic drug candidate birinapant (formerly TL32711) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) bein...

Sutter Health Gives $150,000 to American Red Cross for Oklahoma Tornado Relief

SACRAMENTO, Calif., May 22, 2013 /PRNewswire/ -- Sutter Health today announced a $150,000 donation to the American Red Cross Capital Region Chapter to support relief efforts following the devastating tornado in Oklahoma this week. "It's almost impossible to comprehend the staggering devastation caused by the massive tornado," said Pat Fry, president and CEO of Sutter Health. "Our hearts are with...

Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer

Dr. Olson’s Extensive Experience in Personalized Medicine Will Support Syros’ Mission to Lead in Gene Control Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Eric R. Olson, Ph.D., has joined the company a

Mayo Clinic Forms Joint Venture with Cancer Genetics

OncoSpire Genomics will seek to discover and commercialize biomarkers for multiple cancer types Mayo Clinic ("Mayo") and Cancer Genetics Inc. (OTCQB: CGIX) today launched OncoSpire Genomics ("OncoSpire"), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage